PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2026International Journal of Retina and Vitreous0 citationsOpen Access

Biosimilars of Anti-VEGF Agents for Retinal Diseases: Review of Regulatory and Clinical Aspects

Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuan ZongQFQiwei FanLHLijun Huang

Discussion

Loading...

Member takes

Overview

Narrative review outlines regulatory standards and clinical efficacy of anti-VEGF biosimilars in retinal diseases, indicating safe integration into practice.

Key Points

  • This review aims to consolidate evidence on the regulatory, clinical, and pharmacoeconomic aspects of anti-VEGF biosimilars for retinal diseases.
  • Conducted a narrative review of regulatory documents from FDA, EMA, and NMPA.
  • Analyzed Phase III clinical trials, real-world studies, and pharmacoeconomic evaluations.
  • Included studies from 2015 to 2025 that reported on regulatory approval, efficacy, and safety of anti-VEGF biosimilars.
  • Regulatory reviews confirm rigorous biosimilarity assessment with analytical characterization and clinical trials.
  • Pivotal Phase III studies show therapeutic equivalence of biosimilars, maintaining comparable visual acuity and safety.
  • Pharmacoeconomic data indicates a 20-40% cost reduction compared to originators, enhancing patient access.

Cite This Study

Zong et al. (2026) studied this question.

synapsesocial.com/papers/6a1d234302fbce9130638e49https://doi.org/10.1186/s40942-026-00872-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biosimilars in Retinal Disorders: Cost Revolution or Clinical Trade-off in the Indian Scenario?2025
  2. 2Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India.2026
  3. 3Effectiveness and Safety of Biosimilar Anti-Vascular Endothelial Growth Factor for Retinal Diseases: A Systematic Review and Meta-Analysis2026
  4. 4ADVANCEMENTS IN OPHTHALMIC BIOSIMILARS: A PARADIGM SHIFT IN RETINAL DISEASE MANAGEMENT2024
  5. 5The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity2025 · 1 citations